Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.
Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
Cantor Fitzgerald reiterated their overweight rating on shares of Alector (NASDAQ:ALEC – Free Report) in a research report ...
BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9.Don't Miss our Black Friday Offers:Unlock ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
Alector Inc (ALEC) stock saw a decline, ending the day at $2.16 which represents a decrease of $-0.04 or -1.82% from the prior close of $2.2. The stock opened at $2.27 and touched a low of $2.06 ...
As previously reported, BofA downgraded Alector (ALEC) to Underperform from Neutral with a price target of $1, down from $9, after ALOO2 missed ...
Alector (NASDAQ:ALEC – Free Report) had its target price lowered by BTIG Research from $16.00 to $5.00 in a research note ...
"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...